Need a specific person's email?
Browse I-Mab Biopharma's employee directory (about 92 employees) and reveal verified emails free.
I-Mab Biopharma's most common email format is First.Last@i-mabbiopharma.com (ex. John.Doe@i-mabbiopharma.com), used for 97% of i-mabbiopharma.com addresses. I-Mab Biopharma uses 3 email patterns.
| Format | Example | Share of i-mabbiopharma.com |
|---|---|---|
| First.Last@i-mabbiopharma.comMost common | John.Doe@i-mabbiopharma.com | |
| LF@i-mabbiopharma.com | DJ@i-mabbiopharma.com | |
| First@i-mabbiopharma.com | John@i-mabbiopharma.com |
Browse I-Mab Biopharma's employee directory (about 92 employees) and reveal verified emails free.
Biotechnology ResearchMaryland, United States51-200 Employees
I-Mab Biopharma is a U.S.-based biotechnology company focused on precision immuno-oncology for cancer. Headquartered in Rockville, Maryland, the company operates in the biotechnology research sector and trades on NASDAQ as IMAB. Its lead program, givastomig, is a bispecific antibody designed to direct the immune system against Claudin 18.2-positive gastric cancers by engaging the 4-1BB co-stimulatory pathway in the tumor microenvironment. Givastomig is in early-phase clinical testing for first-line metastatic gastric cancer with potential applicability to other solid tumors. Early data suggest tumor-targeted T-cell activation with a potentially favorable safety profile, and in 2025 the company presented updated givastomig data at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference.
Most common format
First.Last@i-mabbiopharma.com
Example: John.Doe@i-mabbiopharma.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.